Commercialization And Logistics

  1. Key Considerations For Rapid Microbial Methods For Mycoplasma Detection 5/29/2025

    Learn the importance of demonstrating product specific suitability, defining representative sample, consistent sampling protocols, accommodating volume and turnaround time constraints, and the need to establish equivalence.

  2. Improvements In Scaling And Sequencing For Allogeneic Cell Therapies For Oncology 5/6/2024

    During this segment, Nguyen and Wagner agree that scalability will be a top concern for most CGT companies.

  3. AAV Downstream Challenges: Expert Insights 5/22/2025

    Gain expert insight into the complexities of AAV purification to learn how industry leaders tackle downstream challenges, optimize workflows, and drive innovation in scalable, efficient gene therapy manufacturing solutions.

  4. Market Demand For AAV Vectors 11/13/2023

    Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO detail the key factors driving the adeno associated virus manufacturing market.

  5. CTS OpTmizer One SFM: Thoughtfully Designed Nutrition For T Cells 5/22/2025

    Learn about a novel, next-generation medium with an animal-component-free formulation developed to support the need for a T-cell medium that allows consistent, reproducible, and automated T-cell manufacturing.

  6. Defining The CMC / Clinical Relationship For Allogeneic Cell Therapies 5/6/2024

    During this segment, Nguyen and Wagner define why the relationship between CMC and Clinical is so critical, and they also explain what a mutually beneficial partnership between CMC and Clinical looks like.

  7. Pipeline Progress 8/18/2023

    Experts working on robust pipelines that focus on various therapeutic areas explain how process automation looks different per therapeutic focus area.

  8. Efficient AAV Purification With AAVx And AAV9 Magnetic Beads 6/30/2025

    Explore an alternative to chromatographic affinity capture that eliminates the need for universal nuclease treatment by utilizing magnetic beads with ligands specific to AAV.

  9. Driving The Expansion Of mRNA Into The Therapeutic Sphere 6/5/2025

    Discover the next wave of mRNA therapeutics and how emerging technologies are solving key challenges in downstream processing and analysis to enhance both safety and efficacy.

  10. Driving Down COGS Audience Q&A 8/18/2023

    Expert panelists provide detailed answers to questions submitted in real time by our registrants providing insightful responses regarding analytical challenges to automation, test automation, and more.